Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 23;10(5):e05848.
doi: 10.1002/ccr3.5848. eCollection 2022 May.

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

Olga Benitez Hidalgo  1   2 , M Fernanda Martinez Garcia  1   2 , Agustin Bescos Cabestre  3 , Juan Carlos Juarez Gimenez  4 , Mercedes Gironella Mesa  1   2 , Francesc Bosch Albareda  1   2
Affiliations
Case Reports

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management

Olga Benitez Hidalgo et al. Clin Case Rep. .

Abstract

Extended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.

Keywords: anesthesia; haemophilia B; hematology; neuosurgery; pharmacology; rFIX‐Fc.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Valeri F, Giacchello JA, Dainese C, et al. Extended half‐life rFIX in major surgery—how to improve clinical practice: an intraindividual comparison. Clin Case Rep. 2020;8(3):531‐534. doi: 10.1002/ccr3.2450 - DOI - PMC - PubMed
    1. Hermans C, Apte S, Santagostino E. Invasive procedures in patients with haemophilia: review of low‐dose protocols and experience with extended half‐ life FVIII and FIX concentrates and non‐replacement therapies. Haemophilia. 2021;27(S3):46‐52. doi: 10.1111/hae.13978 - DOI - PubMed
    1. Ar MC, Balkan C, Kavaklı K. Extended half‐life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol. 2019;36(3):141‐154. doi: 10.4274/tjh.galenos.2019.2018.0393 - DOI - PMC - PubMed
    1. Powell JS, Apte S, Chambost H, et al. Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study. Br J Haematol. 2015;168(1):124‐134. - PubMed
    1. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IXFc fusion protein in haemophilia B. N Engl J Med. 2013;369:2313‐2323. doi: 10.1056/NEJMoa1305074 - DOI - PubMed

Publication types

LinkOut - more resources